LAB Relative Valuation
LAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LAB is overvalued; if below, it's undervalued.
Historical Valuation
Standard BioTools Inc (LAB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -10.39. The fair price of Standard BioTools Inc (LAB) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.44
Fair
-26.18
PE
1Y
3Y
5Y
Trailing
Forward
-11.90
EV/EBITDA
Standard BioTools Inc. (LAB) has a current EV/EBITDA of -11.90. The 5-year average EV/EBITDA is -7.78. The thresholds are as follows: Strongly Undervalued below -16.31, Undervalued between -16.31 and -12.05, Fairly Valued between -3.51 and -12.05, Overvalued between -3.51 and 0.76, and Strongly Overvalued above 0.76. The current Forward EV/EBITDA of -11.90 falls within the Historic Trend Line -Fairly Valued range.
-4.83
EV/EBIT
Standard BioTools Inc. (LAB) has a current EV/EBIT of -4.83. The 5-year average EV/EBIT is -5.51. The thresholds are as follows: Strongly Undervalued below -10.90, Undervalued between -10.90 and -8.20, Fairly Valued between -2.82 and -8.20, Overvalued between -2.82 and -0.12, and Strongly Overvalued above -0.12. The current Forward EV/EBIT of -4.83 falls within the Historic Trend Line -Fairly Valued range.
7.12
PS
Standard BioTools Inc. (LAB) has a current PS of 7.12. The 5-year average PS is 2.84. The thresholds are as follows: Strongly Undervalued below -0.26, Undervalued between -0.26 and 1.29, Fairly Valued between 4.40 and 1.29, Overvalued between 4.40 and 5.95, and Strongly Overvalued above 5.95. The current Forward PS of 7.12 falls within the Strongly Overvalued range.
81.44
P/OCF
Standard BioTools Inc. (LAB) has a current P/OCF of 81.44. The 5-year average P/OCF is -1.98. The thresholds are as follows: Strongly Undervalued below -32.59, Undervalued between -32.59 and -17.28, Fairly Valued between 13.33 and -17.28, Overvalued between 13.33 and 28.63, and Strongly Overvalued above 28.63. The current Forward P/OCF of 81.44 falls within the Strongly Overvalued range.
-2768.87
P/FCF
Standard BioTools Inc. (LAB) has a current P/FCF of -2768.87. The 5-year average P/FCF is -95.60. The thresholds are as follows: Strongly Undervalued below -1029.91, Undervalued between -1029.91 and -562.76, Fairly Valued between 371.56 and -562.76, Overvalued between 371.56 and 838.71, and Strongly Overvalued above 838.71. The current Forward P/FCF of -2768.87 falls within the Strongly Undervalued range.
Standard BioTools Inc (LAB) has a current Price-to-Book (P/B) ratio of 1.38. Compared to its 3-year average P/B ratio of 0.00 , the current P/B ratio is approximately 28350.32% higher. Relative to its 5-year average P/B ratio of 1.13, the current P/B ratio is about 22.29% higher. Standard BioTools Inc (LAB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -30.07%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -29.07% , the current FCF yield is about -100.00% lower.
1.38
P/B
Median3y
0.00
Median5y
1.13
-17.77
FCF Yield
Median3y
-30.07
Median5y
-29.07
Competitors Valuation Multiple
The average P/S ratio for LAB's competitors is , providing a benchmark for relative valuation. Standard BioTools Inc Corp (LAB) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -56.52%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LAB decreased by 17.71% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -59.90 to -162.05.
The secondary factor is the Revenue Growth, contributed -56.52%to the performance.
Overall, the performance of LAB in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Standard BioTools Inc (LAB) currently overvalued or undervalued?
What is Standard BioTools Inc (LAB) fair value?
How does LAB's valuation metrics compare to the industry average?
What is the current P/B ratio for Standard BioTools Inc (LAB) as of Dec 05 2025?
What is the current FCF Yield for Standard BioTools Inc (LAB) as of Dec 05 2025?
What is the current Forward P/E ratio for Standard BioTools Inc (LAB) as of Dec 05 2025?